What Unichem Labs does

Unichem Laboratories Ltd is an Indian pharmaceutical company that manufactures active pharmaceutical ingredients (API) and finished formulations, supplying global pharmaceutical companies across 65 export markets. The company operates a USFDA-inspected API manufacturing facility at Kolhapur, India, and is in the process of closing its Ireland facility with production shifting to India — a move expected to generate ₹40-50 crore in annual savings and lift EBITDA margin toward 12-13% in FY27. Exports account for 97.6% of FY26 turnover, with US and UK identified as the primary growth markets served under USFDA and MHRA regulatory frameworks.

Unichem is publicly listed on Indian stock exchanges (NSE: UNICHEMLAB) and operates as a subsidiary of Ipca Laboratories, which controls strategic and operational direction. The company employs 2,815 people as of FY26 and invested ₹107.02 crores in R&D during the year to support its API and formulation portfolio. Headquartered in Mumbai, Unichem runs a direct B2B sales motion targeting enterprise pharmaceutical buyers, with marketing concentrated on industry conferences, regulatory engagement, and compliance-led positioning. In July 2026, London-based Polunin Capital Partners acquired a 0.85% stake for ₹38.84 crore through its emerging-markets small-cap fund, marking a notable institutional endorsement of the turnaround.

Name

Unichem Labs

Legal name

Unichem Laboratories Ltd

Website

https://unichemlabs.com

Company type

Public

Founded year

1962

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Unichem Laboratories is an Indian pharmaceutical manufacturer of APIs and formulations, supplying global pharma companies across 65 export markets with US and UK as primary regulated growth markets; operates as an Ipca Laboratories subsidiary.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Small-Molecule API Commercial Manufacturing (HLAGAHAB)

akta.pro secondary industry

Generic APIs & Intermediates (Active Ingredients) (HLAIABAG)

Keywords

• Active pharmaceutical ingredients
• Pharmaceutical formulations
• Generic drug manufacturing
• API manufacturing
• Pharmaceutical exports

Headquarters

HQ city

Mumbai

HQ country

India

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Personnel, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Exports: Exports account for 97.6% of total turnover. Products exported to 65 international markets including US and UK markets.
2. Formulations and API Sales: Revenue from manufacturing and sale of pharmaceutical formulations and active pharmaceutical ingredients to global pharmaceutical companies.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Core offering

Unichem Labs manufactures Active Pharmaceutical Ingredients (APIs) and finished pharmaceutical formulations for global markets. The company operates manufacturing facilities including a USFDA-approved API plant in Kolhapur, India, and exports to 65 international markets, with regulated markets in the US and UK serving as primary growth drivers. It functions as a subsidiary of Ipca Laboratories.

Product overview

Unichem Laboratories is a pharmaceutical company and subsidiary of Ipca Laboratories. The company operates in the active pharmaceutical ingredients (API) manufacturing sector and export formulations business. It maintains manufacturing facilities including a Kolhapur API facility and previously operated a facility in Ireland which is being closed with production shifting to India. The company exports to 65 markets worldwide with exports accounting for 97.6% of total turnover in FY26.

Differentiator

Problem solved

Functional benefit

Products and services

• Active Pharmaceutical Ingredients (APIs)
• Pharmaceutical Formulations

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators12 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Glenmark Pharmaceuticals: Indian pharma player with a US-led generics, API, and specialty business. Comparable on US/UK regulated markets, API manufacturing scale, and B2B customer mix.
• Aurobindo Pharma: Indian-listed generics and API manufacturer with deep US/UK regulated-market presence and a large USFDA-cleared API and injectable footprint. Closest large-cap comparable to Unichem on API-and-formulation dual model targeting 65+ export markets.
• Lupin: Indian-listed pharmaceutical company with a US-led generics franchise, complex API capabilities, and USFDA-inspected manufacturing. Matches Unichem on regulated-market generics + API exposure and export-led revenue mix.
• Divi's Laboratories: India's largest pure-play API manufacturer focused on custom synthesis and generics APIs for global innovator and generics customers. Highly comparable on API-only manufacturing model, USFDA-inspected facilities, and export-driven revenue.
• Granules India: Indian-listed pharmaceutical manufacturer focused on APIs, intermediates and finished dosages with a large US generics franchise. Closely comparable on USFDA-regulated API and formulation output serving US/global B2B buyers.
• Dr. Reddy's Laboratories: Indian-listed pharmaceutical company with global generics, API, and biosimilars operations selling primarily to US/UK/EU regulated markets. Overlaps directly with Unichem on USFDA-inspected API manufacturing and B2B drug-substance supply.
• Cipla: One of India's largest pharma exporters with deep US/UK/South Africa presence, an API business, and USFDA-inspected facilities. Comparable business model and customer base (regulated-market generics buyers).
• Ipca Laboratories: Parent company of Unichem and itself a major Indian API + formulations exporter with strong branded-generics presence in India and global markets. Directly comparable on product mix, API manufacturing capabilities, and export geography.

Broad incumbents

• Zydus Lifesciences (Cadila Healthcare): Indian integrated pharma company with US generics, API, vaccines, and consumer healthcare lines. Wider product breadth than Unichem but overlapping on USFDA-cleared API facilities and US export focus.
• Sun Pharmaceutical Industries: India's largest pharma company with a broad generics, API, and specialty portfolio across US/India/emerging markets. Larger incumbent with overlapping API manufacturing and US generics distribution; not niche-comparable, but a benchmark on USFDA standing and export mix.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Unichem Labs